XTL Biopharmaceuticals Stock (NASDAQ:XTLB)


OwnershipFinancialsChart

Previous Close

$1.45

52W Range

$0.77 - $4.99

50D Avg

$1.83

200D Avg

$2.32

Market Cap

$21.41M

Avg Vol (3M)

$42.40K

Beta

1.00

Div Yield

-

XTLB Company Profile


XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IL

Employees

8

IPO Date

Sep 01, 2005

Website

XTLB Performance


XTLB Financial Summary


Dec 23Dec 22Dec 21
Revenue-$-459.00K$1.47M
Operating Income$-765.00$-880.00K$-1.03M
Net Income$-1.78K$-2.31M$1.90M
EBITDA$-764.00$-386.00K$-2.50M
Basic EPS-$-0.42$0.36
Diluted EPS-$-0.42$0.36

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
PRPHProPhase Labs, Inc.
BOSCB.O.S. Better Online Solutions Ltd.
XBIOXenetic Biosciences, Inc.
BNTCBenitec Biopharma Inc.